Related Experiment Video

Updated: Sep 1, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease

Nicholas P Jenkins1, Brian G Keevil, Ian V Hutchinson

  • 1University Department of Cardiology, Regional Cardiac Centre, Wythenshawe Hospital, Manchester, United Kingdom.

The American Journal of Medicine
|March 15, 2002
PubMed

Insights

Beta-blockers significantly lower C-reactive protein (CRP) levels in patients with coronary artery disease. Further randomized studies are needed to confirm this association and its clinical implications for cardiovascular risk.

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Biomarkers

Background:

  • C-reactive protein (CRP) is a key inflammatory marker and risk factor for coronary artery disease (CAD).
  • Pravastatin and aspirin are known to reduce plasma CRP concentrations.
  • The impact of other cardiovascular drugs on CRP levels remains less understood.

Purpose of the Study:

  • To investigate the effect of beta-blockers on C-reactive protein concentrations in patients with stable angina and confirmed coronary artery disease.

Main Methods:

  • A high-sensitivity immunonephelometric assay was used to measure plasma CRP in 333 patients.
  • Patients with stable angina undergoing diagnostic angiography were included.
  • Statistical analyses adjusted for potential confounders, including propensity scores.

Main Results:

  • Patients treated with beta-blockers exhibited significantly lower mean CRP concentrations compared to those not on beta-blockers (40% difference).
  • This association persisted after adjusting for contraindications, propensity scores, and other clinical predictors of CRP.
  • No significant differences in CRP levels were observed among different types or dosages of beta-blockers.

Conclusions:

  • Beta-blocker therapy may influence C-reactive protein concentrations in patients with coronary artery disease.
  • Randomized controlled trials are necessary to validate these findings and elucidate the clinical significance.
Abstract

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...